NASD · Healthcare · Biotechnology · USA
Agios Pharmaceuticals Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Agios Pharmaceuticals is a biopharmaceutical company developing medicines for rare diseases, primarily in hematology. Its lead product, mitapivat, is approved in multiple markets for treating hemolytic anemias including thalassemia and pyruvate kinase deficiency, as well as sickle cell disease. The company also develops other candidates targeting rare blood disorders and metabolic diseases.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Agios Pharmaceuticals Inc stock.
Overvalued: intrinsic value $15.69 per share, market price $29.89, margin of safety -90.6% (as of 2026-11-17).
A 2.4x revenue multiple, discounted for its losses, values the shares at $15.69; the price of $29.89 is 91% above that value.
17 more funds hold it; the full list is part of the paid plan.
53 more in this industry show a wider margin of safety.
AGIO is overvalued (as of the 2026-11-17 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $15.69; the price of $29.89 is 91% above that value.
$15.69 per share (as of the 2026-11-17 close), against a market price of $29.89. That is a margin of safety of -90.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.